You are in: eMedicine Specialties > Pediatrics: General Medicine > Pulmonology Primary Ciliary DyskinesiaArticle Last Updated: Sep 25, 2008AUTHOR AND EDITOR INFORMATIONAuthor: Girish D Sharma, MD, Associate Professor, Department of Pediatrics, Rush University Medical Center, Rush Children's Hospital; Director of Pediatric Pulmonary Section and Rush Cystic Fibrosis Center Girish D Sharma is a member of the following medical societies: American Academy of Pediatrics, American College of Chest Physicians, American Thoracic Society, and Royal College of Physicians of Ireland Editors: Susanna A McColley, MD, Director of Cystic Fibrosis Center; Head, Division of Pulmonary Medicine; Associate Professor, Department of Pediatrics, Children's Memorial Medical Center of Chicago, Northwestern University; Mary L Windle, PharmD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy, Pharmacy Editor, eMedicine; Heidi Connolly, MD, Associate Professor of Pediatrics and Psychiatry, University of Rochester; Director, Pediatric Sleep Medicine Services, Strong Sleep Disorders Center; Mary E Cataletto, MD, Associate Director, Division of Pediatric Pulmonology, Winthrop University Hospital; Professor of Clinical Pediatrics, State University of New York at Stony Brook; Director of Children's Sleep Services, Winthrop University Hospital; Michael R Bye, MD, Attending Physician, Pediatric Pulmonary Medicine, Columbia University Medical Center; Professor of Clinical Pediatrics, Division of Pulmonary Medicine, Columbia University College of Physicians and Surgeons Author and Editor Disclosure Synonyms and related keywords: primary ciliary dyskinesia, PCD, immotile cilia syndrome, ICS, cilia, dyskinetic cilia syndrome, immotile cilia syndrome, Kartagener syndrome, situs inversus totalis, respiratory infections, sinusitis, otitis media, male infertility, chronic sinusitis, bronchiectasis, ciliary dyskinesia syndrome, CDS, male infertility, rhinitis, pneumonia, dextrocardia, rhinorrhea, anosmia, halitosis, hydrocephalus, atelectasis, nasal mucosal congestion, mucopurulent nasal discharge, nasal obstruction, nasal polyps INTRODUCTIONBackgroundImmotile cilia syndrome (ICS) is an autosomal recessive disease with extensive genetic heterogeneity characterized by abnormal ciliary motion and impaired mucociliary clearance. Ultrastructural and functional defects of cilia result in the lack of effective ciliary motility, causing abnormal mucociliary clearance. This leads to recurrent or persistent respiratory infections, sinusitis, otitis media, and male infertility. In 50% of the patients, ICS is associated with situs inversus. In 1933, Kartagener described a unique syndrome characterized by the triad of situs inversus, chronic sinusitis, and bronchiectasis, which was dubbed Kartagener syndrome.1, 2 Later, patients with this condition were noted to have defects in the ultrastructure of cilia. Afzelius coined the term immotile cilia.3 Later studies showed that disorganized motion, rather than immotile cilia, resulted in the uncoordinated and ineffective ciliary beat, hence the term ciliary dyskinesia syndrome (CDS). Because transient ciliary dyskinesia may be acquired following epithelial injury from viral respiratory tract infections or exposure to pollutants,4, 5 the term primary ciliary dyskinesia (PCD) is used to describe the genetic defect and to differentiate it from acquired defects. Review of normal and abnormal ciliary ultrastructure The epithelial lining of the large airways and contiguous structures, including the paranasal sinuses, middle ears, and posterior nose, consists of ciliated pseudostratified columnar epithelium. Ciliated cells are also found in the ependymal lining of the brain and fallopian tubes. In addition, the spermatozoal flagella (tail of spermatozoa) has a core structure that is identical to cilia. Each matured ciliated cell has up to 200 cilia. Each cilium has an array of longitudinal microtubules arranged as 9 doublets formed in an outer circle around a central pair (see Media file 1). The main structural protein of these doublets is tubulin. The microtubules are anchored by a basal body in the apical cytoplasm of the cell. Radial spokes connect the outer microtubular doublets with a central sheath of protein around the central tubules. Cross-section of the cilia (see Media file 1) reveals inner and outer dynein arms, which are attached to the A subunit of each microtubule doublet. The inner dynein arms are longer and form a hook, whereas the outer dynein arms are short and straight. Dynein, a type of ATPase, provides energy for microtubule sliding and the longitudinal displacement of adjacent microtubular doublets, resulting in ciliary bending. The protein nexin links the outer microtubular doublets, creating a circumferential network as straplike bands. Because nexin links maintain axonemal relationships while the basal bodies anchor the microtubules, the sliding of the outer microtubule results in bending of the cilium. Ciliary movement involves 2 phases: an effective stroke phase that sweeps forward and a recovery phase during which the cilia bend backward and extend into the starting position for the stroke phase. The mucous lining present on the respiratory epithelium has an inner serous layer called the sol phase, in which the cilia recover from their active beat, and an outer, more viscous layer, the gel phase. The tips of the cilia contact the gel layer during the stroke phase to propel the secretions forward, but the cilia lose contact with the gel layer of the mucus during the recovery phase. Normal ciliary beat frequency is 1000-1500 beats per minute. The frequency is slower in the peripheral airways (eg, bronchioles) compared to the larger airways (eg, trachea). The ciliary motility is maintained in the same plane along the length of airways and results in mucociliary transport rates up to 20-30 mm/min. PathophysiologyDefects in the ciliary component cause abnormal ciliary movements, resulting in impaired mucociliary clearance and manifesting as recurrent and or persistent sinopulmonary infections, among other problems. Dynein arm defects manifest as a total or a partial absence of either both inner or both outer dynein arms or involve just the inner or outer arms. Sometimes, shortened dynein arms are the only defect. Recent studies show differential functions of both inner and outer dynein arms and correlate ciliary beat frequency directly with the number of outer dynein arms. The ciliary beat frequency is not correlated with the number of inner dynein arms. Radial spoke defects exhibit either a total absence of radial spokes or an absence of radial spoke heads. These defects are easily recognized by an eccentric position of the central pair of microtubules that are normally stabilized in a central position by radial spokes. Microtubular transposition defects occur in the form of absence of the central pair of tubules with transposition of the outer doublet to the center. Other defects, such as ciliary aplasia, ciliary disorientation,6 malaligned central pair of microtubules in adjacent cilia, and basal body abnormalities may occur after viral infections, making it unclear if they are primary or secondary defects. Moreover, in some patients with typical clinical manifestations of PCD, the ciliary ultrastructure may appear normal, suggesting functional abnormalities because of other defects in ciliary components. Recent studies have confirmed that ciliary beat pattern is associated with specific ultrastructural defects in PCD.7 New high-resolution digital high-speed video (DHSV) imaging has allowed the precise beat pattern of cilia to be viewed in 3 different planes in slow motion or frame-by-frame. Using this technique, 3 patterns were identified and correlated with ultrastructural defects. In the first pattern, the cilia are virtually immotile with occasional slow, low-amplitude, stiff flickering motion. This is associated with either a combined inner and outer dynein arm defect or isolated outer dynein arm defect. In the second pattern, the cilia have stiff planar forward-backward motion with markedly reduced amplitude, a pattern associated with either an isolated inner dynein arm defect or a radial spoke defect. In the third pattern, the cilia beat in a large circular gyrating motion about the base of the cilium. This pattern is associated with transposition defect. FrequencyUnited StatesThe prevalence of PCD is approximately 1:16,000 live births. Geographic area and consanguinity may affect the prevalence. Specific types of defects are consistent within individual families and appear to be genetically determined. Based on the autosomal recessive mode of inheritance, the probability of having subsequent children with PCD is 1:4. Mortality/MorbidityMorbidity includes chronic, persistent, or recurrent sinusitis, rhinitis, pneumonia, and otitis media. Male infertility is common. Evidence of female infertility is inconclusive. Progression of lung disease varies and is affected by age at diagnosis, ability of medical treatment to control the symptoms, and prevention of complications. These factors affect the quality of life. Individuals with normal or near normal lifespan have been reported. No studies have examined the impact of current symptomatic therapies on the course of disease. RaceNo racial predilection is reported. SexNo sex predilection is reported. AgeNo particular age predilection is recognized; infants are born with this genetic disorder. Cases associated with dextrocardia and with respiratory symptoms are more likely to be diagnosed in early infancy. CLINICALHistoryClinical manifestations vary.
Physical
CausesPrimary ciliary dyskinesia (PCD) is a genetic disorder, and it appears to follow the autosomal recessive inheritance pattern. Two genes directly implicated in autosomal recessive PCD are DNAI1 and DNAH5, which encode for components of the outer dynein arm complex.9, 10, 11, 12 Mutations in these genes are detected in 38% of patients with PCD. Commercial testing for these mutations is available and may help with the diagnosis. DIFFERENTIALSCystic Fibrosis
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Drug Name | Amoxicillin (Trimox, Amoxil) |
|---|---|
| Description | A penicillin antibiotic with activity against gram-positive and some gram-negative bacteria. Binds to PBPs, inhibiting bacterial cell wall growth. |
| Adult Dose | 250-500 mg PO tid |
| Pediatric Dose | 40 mg/kg/d PO divided tid |
| Contraindications | Documented hypersensitivity |
| Interactions | Decreases PO contraceptive efficacy; probenecid increases amoxicillin serum concentration |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | May develop rash and diarrhea; caution in those allergic to cephalosporin antibiotics |
| Drug Name | Amoxicillin and clavulanic acid (Augmentin) |
|---|---|
| Description | Combination product that extends the antibiotic spectrum of this penicillin to include bacteria normally resistant to beta-lactam antibiotics. Different amoxicillin/clavulanic acid ratios are recognized. (eg, 250-mg tab [250/125] vs 250-mg chewable tab [250/62.5]). Do not use products containing 125 mg of clavulanate until child weighs >40 kg. Note different product ratios for bid and tid dosing schedules. |
| Adult Dose | 250-500 mg PO tid; alternatively, 875 mg PO bid |
| Pediatric Dose | 20-40 mg/kg/d PO divided tid; not to exceed 2 g/d of amoxicillin component Supplied as 125-mg and 250-mg chewable tablets with 31.25 and 62.5 mg clavulanate, respectively, or as 125- and 250-mg/5 mL suspension with 31.25 mg and 62.5 mg of clavulanate per 5 mL, respectively Alternatively, 25-45 mg/kg/d PO divided bid; supplied as 200-mg and 400-mg chewable tab with 28.5 and 57 mg clavulanate, respectively, or as 200- and 400-mg/5 mL suspension with 28.5 mg and 57 mg of clavulanate per 5 mL, respectively |
| Contraindications | Documented hypersensitivity |
| Interactions | Allopurinol may increase incidence of rash |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Rash and gastrointestinal upset are some of the more common adverse reactions; newer formulation for bid dosing is associated with less diarrhea; bid dosing preparations contain phenylalanine and should not be prescribed for patients with PKU; caution in patients allergic to cephalosporin antibiotics |
| Drug Name | Sulfamethoxazole and trimethoprim (Bactrim, Septra) |
|---|---|
| Description | Inhibits bacterial growth by inhibiting synthesis of dihydrofolic acid. |
| Adult Dose | 160 mg (as trimethoprim component) per 800 mg (as sulfamethoxazole component) PO q12h (ie, 1 double-strength tab q12h) |
| Pediatric Dose | 5-10 mg/kg/d (based on trimethoprim component) PO divided bid |
| Contraindications | Documented hypersensitivity; megaloblastic anemia caused by folate deficiency (avoid); administration in infants <2 mo; G-6-PD deficiency |
| Interactions | May increase PT when used with warfarin (perform coagulation tests and adjust dose accordingly); coadministration with dapsone may increase blood levels of both drugs; coadministration of diuretics increases prevalence of thrombocytopenia purpura in elderly people; phenytoin levels may increase with coadministration; may potentiate effects of methotrexate in bone marrow depression; hypoglycemic response to sulfonylureas may increase with coadministration; may increase levels of zidovudine |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | May cause hepatic necrosis; aplastic anemia; agranulocytosis; hemolysis may occur in G-6-PD deficiency and is frequently dose-related |
| Drug Name | Erythromycin and sulfisoxazole (Pediazole) |
|---|---|
| Description | Erythromycin is a macrolide antibiotic with a large spectrum of activity. Erythromycin binds to the 50S ribosomal subunit of the bacteria, which inhibits protein synthesis. Sulfisoxazole expands erythromycin's coverage to include gram-negative bacteria. Sulfisoxazole inhibits bacterial synthesis of dihydrofolic acid by competing with para-aminobenzoic acid. |
| Adult Dose | Not established |
| Pediatric Dose | 50 mg/kg/d (as erythromycin) PO divided qid; not to exceed 2 g/d erythromycin or 6 g/d sulfisoxazole |
| Contraindications | Documented hypersensitivity; hepatic impairment; concomitant administration of terfenadine, theophylline, cisapride, and astemizole; administration to infants <2 mo; G-6-PD deficiency |
| Interactions | Erythromycin decreases the clearance of terfenadine, cisapride, and astemizole, which may result in serious cardiac arrhythmias; erythromycin decreases the clearance of cyclosporine, midazolam, phenytoin, triazolam, and theophylline; erythromycin may increase the toxicity of warfarin and ergotamine |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Hemolysis may occur in G-6-PD deficiency and frequently is dose-related; use with caution in patients with renal or hepatic impairment |
Inhaled bronchodilators are used to treat associated bronchospastic symptoms or before chest physical therapy to help airway clearance.
| Drug Name | Albuterol (Proventil, Ventolin) |
|---|---|
| Description | May be administered as either metered dose inhaler or nebulized form. Beta-agonist for bronchospasm refractory to epinephrine. Relaxes bronchial smooth muscle by action on beta2-receptors with little effect on cardiac muscle contractility. |
| Adult Dose | Metered dose inhaler: 180 mcg (2 actuations, 90 mcg per actuation) inhaled q4-6h |
| Pediatric Dose | Metered dose inhaler: Administer as in adults Nebulization: 2.5 mg (0.5 mL of 0.5% solution diluted in 2-3 mL 0.9% NaCl) inhaled via nebulizer q4-6h |
| Contraindications | Documented hypersensitivity; beta-agonist therapy (some patients with bronchiectasis may have a paradoxical constriction of the airways with beta-agonist therapy) |
| Interactions | Antagonized by beta-antagonists (eg, propranolol); cardiovascular effects may increase with MAOIs, inhaled anesthetics, tricyclic antidepressants, and sympathomimetic agents |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Muscular tremors, tachycardia, hyperglycemia, or hypokalemia may occur with high and very frequent doses |
Anti-inflammatory agents are used to treat inflammation associated with chronic and recurrent pulmonary infections. Various inhaled corticosteroids are used.
Inhaled corticosteroids are the most commonly used anti-inflammatory agents. Various preparations are available in metered dose inhaler form. Recently, a nebulized form of budesonide was approved and made available.
| Drug Name | Beclomethasone (Beclovent, Vanceril) |
|---|---|
| Description | Inhibits bronchoconstriction mechanisms. Produces direct smooth muscle relaxation. May decrease number and activity of inflammatory cells, in turn decreasing airway hyperresponsiveness. |
| Adult Dose | 84 mcg (42 mcg per actuation) inhaled PO tid/qid |
| Pediatric Dose | 4-12 inhalations per d PO (42 mcg per actuation) divided tid/qid |
| Contraindications | Documented hypersensitivity |
| Interactions | None reported |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Inhaled corticosteroids can cause PO thrush and hoarseness of voice (prevented by rinsing mouth after a dose and using spacer with MDI); very large doses (>800 mcg/d) have been shown to have systemic adverse effects, including growth retardation |
| Drug Name | Fluticasone (Flovent) |
|---|---|
| Description | Inhibits bronchoconstriction mechanisms. Produces direct smooth muscle relaxation. May decrease number and activity of inflammatory cells, in turn decreasing airway hyperresponsiveness. |
| Adult Dose | 88 (44 mcg per actuation) inhaled PO bid initially; may increase prn; not to exceed 440 mcg bid |
| Pediatric Dose | 4-11 years: 50-100 mcg (using Diskus) inhaled PO bid >11 years: 44-132 mcg (1-3 inhalations of 44 mcg per actuation) inhaled PO bid; alternatively 110 mcg (1 inhalation of 110 mcg per actuation) bid |
| Contraindications | Documented hypersensitivity |
| Interactions | Drugs that are metabolized by the CYP3A4 isoenzyme (ie, ketoconazole) may increase fluticasone concentrations |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Inhaled corticosteroids can cause PO thrush and hoarseness of voice (prevented by rinsing mouth after a dose and using spacer with MDI); very large doses (>800 mcg/d) have been shown to have systemic adverse effects, including growth retardation |
| Drug Name | Budesonide (Pulmicort) |
|---|---|
| Description | The nebulized form (ie, Respules) is now approved by the FDA, allowing younger children the benefit of administration. Alters level of inflammation in airways by inhibiting multiple types of inflammatory cells and decreasing production of cytokines and other mediators involved in the asthmatic response. Available as dry inhaled powder (Flexhaler - 90 mcg/actuation [delivers 80 mcg]; Turbuhaler – 200 mcg/actuation [delivers 160 mcg]) or suspension for nebulization (Respules). |
| Adult Dose | Metered dose inhaler: 200-400 mcg inhaled PO bid initially; may increase to 800 mcg bid |
| Pediatric Dose | Metered dose inhaler: 200-400 mcg/d (200 mcg per actuation) inhaled PO Nebulized form (Respules): 0.25-0.5 mg inhaled via nebulizer qd/bid |
| Contraindications | Documented hypersensitivity |
| Interactions | None reported |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Inhaled corticosteroids can cause PO thrush and hoarseness of voice (prevented by rinsing mouth after a dose and using spacer with MDI); very large doses (>800 mcg/d) have been shown to have systemic adverse effects, including growth retardation |
| Media file 1: Diagram showing the cross-section of normal cilia showing its ultrastructure. Important components are labeled. | |
![]() | View Full Size Image | Media type: Image |
Primary Ciliary Dyskinesia excerpt
Article Last Updated: Sep 25, 2008